Literature DB >> 6344591

On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.

D K Reilly, L Hershey, L Rivera-Calimlim, I Shoulson.   

Abstract

Patients with PD who experience on-off effects have higher erythrocyte catechol-O-methyltransferase (COMT) activities and plasma 3-O-methyldopa concentrations than do patients without these levodopa-related motor fluctuations. We therefore administered ascorbic acid, a weak competitive inhibitor of COMT, to six PD patients with on-off effects. In this double-blind crossover investigation, ascorbic acid produced a modest improvement in functional performance. However, no fundamental change was observed in the pattern of on-off effects, severity of parkinsonism/dyskinesia, or self-assessment ratings. Ascorbic acid therapy reduced plasma concentrations of levodopa and 3-O-methyldopa but did not alter erythrocyte COMT activity. These findings are discussed in the context of the pharmacokinetic and pharmacodynamic factors that contribute to the pathogenesis of levodopa-induced dyskinesias and on-off motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344591

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  10 in total

1.  Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT.

Authors:  Kathryn T Hall; Joseph Loscalzo; Ted J Kaptchuk
Journal:  Pharmacogenomics       Date:  2019-05       Impact factor: 2.533

2.  Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.

Authors:  M Lazzarini; C Salum; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 3.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.

Authors:  Hironori Yokoyama; Sho Takagi; Yu Watanabe; Hiroyuki Kato; Tsutomu Araki
Journal:  J Neural Transm (Vienna)       Date:  2008-01-31       Impact factor: 3.575

5.  Nutritional therapies in Parkinson's disease.

Authors:  Marian L Evatt
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

Review 6.  Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases.

Authors:  Morgana Moretti; Daiane Bittencourt Fraga; Ana Lúcia S Rodrigues
Journal:  CNS Neurosci Ther       Date:  2017-10-04       Impact factor: 5.243

7.  Initiation of treatment in early PD (evidences based).

Authors: 
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

Review 8.  N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.

Authors:  Reza Bavarsad Shahripour; Mark R Harrigan; Andrei V Alexandrov
Journal:  Brain Behav       Date:  2014-01-13       Impact factor: 2.708

Review 9.  N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology.

Authors:  Motoki Arakawa; Yoshihisa Ito
Journal:  Cerebellum       Date:  2007-01-19       Impact factor: 3.847

10.  Systematic Surveys of Iron Homeostasis Mechanisms Reveal Ferritin Superfamily and Nucleotide Surveillance Regulation to be Modified by PINK1 Absence.

Authors:  Jana Key; Nesli Ece Sen; Aleksandar Arsović; Stella Krämer; Robert Hülse; Natasha Nadeem Khan; David Meierhofer; Suzana Gispert; Gabriele Koepf; Georg Auburger
Journal:  Cells       Date:  2020-10-02       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.